[go: up one dir, main page]

PE20190566A1 - Aumento de la fertilidad en especies bovinas - Google Patents

Aumento de la fertilidad en especies bovinas

Info

Publication number
PE20190566A1
PE20190566A1 PE2019000260A PE2019000260A PE20190566A1 PE 20190566 A1 PE20190566 A1 PE 20190566A1 PE 2019000260 A PE2019000260 A PE 2019000260A PE 2019000260 A PE2019000260 A PE 2019000260A PE 20190566 A1 PE20190566 A1 PE 20190566A1
Authority
PE
Peru
Prior art keywords
fertility
increase
bovine species
immunomodulation
immunogen
Prior art date
Application number
PE2019000260A
Other languages
English (en)
Inventor
Jason Nickell
Daniel Keil
Albert Abraham
Warren Tully
Riekerink Richard Gerhardus Martinu Olde
Terry Settje
Leland Vickers
Stuart Nibbelink
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20190566A1 publication Critical patent/PE20190566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones y metodos de inmunomodulacion que son eficaces para aumentar el porcentaje de concepcion de vacas. La composicion inmunomoduladora comprende un vehiculo de administracion de liposomas cationicos y una molecula de acido nucleico derivada de bacterias aisladas que no codifica para un inmunogeno
PE2019000260A 2016-07-26 2017-07-25 Aumento de la fertilidad en especies bovinas PE20190566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
PE20190566A1 true PE20190566A1 (es) 2019-04-22

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000260A PE20190566A1 (es) 2016-07-26 2017-07-25 Aumento de la fertilidad en especies bovinas

Country Status (22)

Country Link
US (1) US10933131B2 (es)
EP (1) EP3490598A1 (es)
JP (1) JP2019525935A (es)
KR (1) KR102473370B1 (es)
CN (1) CN109689095B (es)
AR (1) AR109167A1 (es)
AU (1) AU2017301528A1 (es)
BR (1) BR112019001599A2 (es)
CA (1) CA3031778A1 (es)
CL (1) CL2019000185A1 (es)
CO (1) CO2019000724A2 (es)
CR (1) CR20190037A (es)
DO (1) DOP2019000018A (es)
IL (1) IL264380A (es)
MX (1) MX386744B (es)
NZ (1) NZ750181A (es)
PE (1) PE20190566A1 (es)
PH (1) PH12019500191A1 (es)
SG (1) SG11201900710YA (es)
TW (1) TWI759317B (es)
UY (1) UY37346A (es)
WO (1) WO2018022583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CN101543507A (zh) * 1999-09-25 2009-09-30 衣阿华大学研究基金会 免疫刺激性核酸
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2006017857A2 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
PT2654785T (pt) * 2010-12-22 2019-06-25 Bayer Ip Gmbh Resposta imunitária melhorada em espécies bovinas
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
CR20160393A (es) * 2014-02-28 2017-12-14 Bayer Animal Health Gmbh Plásmidos inmunoestimuladores
JP2018518511A (ja) 2015-06-26 2018-07-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 細胞質ｄｎａ監視分子の調節方法
DK3328423T3 (da) 2015-07-31 2021-07-26 Bayer Animal Health Gmbh Forbedret immunrespons hos fisk
EP3328424A1 (en) 2015-07-31 2018-06-06 Bayer Animal Health GmbH Enhanced immune response in porcine species

Also Published As

Publication number Publication date
US10933131B2 (en) 2021-03-02
TW201817427A (zh) 2018-05-16
IL264380A (en) 2019-02-28
PH12019500191A1 (en) 2022-04-11
MX2019001126A (es) 2019-08-14
NZ750181A (en) 2023-02-24
US20190388538A1 (en) 2019-12-26
CR20190037A (es) 2019-05-16
WO2018022583A1 (en) 2018-02-01
DOP2019000018A (es) 2019-07-31
SG11201900710YA (en) 2019-02-27
KR102473370B1 (ko) 2022-12-05
CA3031778A1 (en) 2018-02-01
UY37346A (es) 2018-02-28
CN109689095B (zh) 2023-10-03
CO2019000724A2 (es) 2019-02-08
MX386744B (es) 2025-03-19
CN109689095A (zh) 2019-04-26
AR109167A1 (es) 2018-11-07
EP3490598A1 (en) 2019-06-05
AU2017301528A1 (en) 2019-02-14
KR20190032434A (ko) 2019-03-27
TWI759317B (zh) 2022-04-01
JP2019525935A (ja) 2019-09-12
CL2019000185A1 (es) 2019-06-28
BR112019001599A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR102014027466A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de soja, método para preparação de uma célula de planta transgênica, e loci genômicos de soja não gênicos purificados
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112018007622A2 (pt) ferramenta genética de transformação de bactérias clostridium
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR102014027438A8 (pt) Sequência recombinante, uso de uma planta, de uma parte de planta, ou de uma célula de planta de milho, método para preparação de uma célula vegetal transgênica, e sequências recombinante e genômica de milho
BR102014027442A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de maís, método de preparação de uma célula vegetal transgênica e loci genômicos de maís não gênico purificados
MX2017001279A (es) Usos y composiciones de la flagelina.
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
AR096869A1 (es) Neurotoxinas catiónicas
MX379120B (es) Silanos y composiciones curables que contienen dichos silanos como reticulantes.
CL2018001546A1 (es) Formulaciones líquidas que contienen fungicidas
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
ZA201901168B (en) Novel compounds for treating parasitic disease
ECSP18024466A (es) Composiciones de micropartículas que comprenden saflufenacil
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
PE20190566A1 (es) Aumento de la fertilidad en especies bovinas
EA201892003A1 (ru) Лечение атопического дерматита собак
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CO2017001320A2 (es) Composición de lhrh inmunogénica
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112016018594B8 (pt) Método para produção do derivado de 2-aciliminopiridina